Aktie SIGY SIGYN THERAPEUTICS, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen Sigyn Therapeutics, Inc. Other OTC

Aktien

SIGY

US82674U1060

SIGY

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Sigyn Therapeutics Discloses Publication of "Sigyn Therapy, an Emerging Candidate to Address Endotoxemia, Sepsis, and Drug-Resistant Viral & Bacterial Infections"
Sigyn Therapeutics™ to Present at Tomorrow’s Emerging Growth Conference
Sigyn Therapeutics™ Announces Filing of 2023 Annual Report on SEC Form 10-K
Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Sigyn Therapeutics Announces Reverse Stock Split
Sigyn Therapeutics Releases Letter to Shareholders
Sigyn Therapeutics, Inc. Appoints Jerry Deciccio as Chief Financial Officer
Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer
Sigyn Therapeutics Reports Third Quarter 2023 Financial Results
Sigyn Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Sigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity
Sigyn Therapeutics to Present at Today’s Emerging Growth Conference and Tomorrow at the National Investment Bankers Association Conference
Sigyn Therapeutics Reports Second Quarter 2023 Financial Results
Sigyn Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Sigyn Therapeutics to Present at Tomorrow’s Emerging Growth Conference
Sigyn Therapeutics to Present at the OTCQB Venture Virtual Investor Conference on August 3rd
Sigyn Therapeutics Discloses “DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES” Patent Submission and Related ImmunePrep™ Trademark Application
Sigyn Therapeutics, Inc. Discloses "DEVICES FOR ENHANCING THE ACTIVITY OF THERAPEUTIC ANTIBODIES" Patent Submission and Related ImmunePrep Trademark Application
Sigyn Therapeutics Reports First Quarter 2023 Financial Results
Sigyn Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A401WX Aktie
  4. SIGY Aktie
  5. Nachrichten Sigyn Therapeutics, Inc.
  6. Andere Sprachen